IMI European Lead Factory - democratizing access to high-throughput screening

14 Dec 2021

Jones PS, Boucharens S, McElroy SP, Morrison A, Honarnejad S, van Boeckel S, van den Hurk H, Basting D, Hüser J, Jaroch S, Ottow E, Benningshof J, Folmer RHA, Leemhuis F, Kramer-Verhulst PM, Nies VJM, Orrling KM, Rijnders T, Pfander C, Engkvist O, Pairaudeau G, Simpson PB, Ortholand JY, Roche D, Dömling A, Kühnert SM, Roevens PWM, van Vlijmen H, van Wanrooij EJA, Verbruggen C, Nussbaumer P, Ovaa H, van der Stelt M, Simonsen KB, Tagmose L, Waldmann H, Duffy J, Finsinger D, Jurzak M, Burgess-Brown NA, Lee WH, Rutjes FPJT, Haag H, Kallus C, Mors H, Dorval T, Lesur B, Ramon Olayo F, Hamza D, Jones G, Pearce C, Piechot A, Tzalis D, Clausen MH, Davis J, Derouane D, Vermeiren C, Kaiser M, Stockman RA, Barrault DV, Swedlow JR, Nelson AS, Orru RVA, Ruijter E, van Helden SP, Li VM, Vries T, de Vlieger JSB

Nature Reviews Drug Discovery
PMID: 34907316

Doi: 10.1038/d41573-021-00196-3

Photo: iStock.com/Viorika

The European Lead Factory combines assets and experience from major pharma with innovation and agility of academia and SMEs in a collaborative platform to expand access to high-throughput screening. With many successes heading towards the clinic, the organization is broadening its approach to screening and partnering.

Small-molecule drug discovery begins with a therapeutic rationale but rapidly progresses to requiring chemical matter to validate the rationale and provide the chemical basis for a potential new medicine.

To view the full article please visit the Nature Reviews Drug Discovery website.